- Home
- KIM vs INSM Comparison
KIM vs INSM Comparison
Compare KIM & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIM
- INSM
- Stock Information
- Founded
- KIM 1958
- INSM 1988
- Country
- KIM United States
- INSM United States
- Employees
- KIM N/A
- INSM N/A
- Industry
- KIM Real Estate Investment Trusts
- INSM Biotechnology: Pharmaceutical Preparations
- Sector
- KIM Real Estate
- INSM Health Care
- Exchange
- KIM Nasdaq
- INSM Nasdaq
- Market Cap
- KIM 15.0B
- INSM 14.3B
- IPO Year
- KIM 1991
- INSM 2000
- Fundamental
- Price
- KIM $21.52
- INSM $81.06
- Analyst Decision
- KIM Buy
- INSM Strong Buy
- Analyst Count
- KIM 17
- INSM 15
- Target Price
- KIM $24.50
- INSM $92.00
- AVG Volume (30 Days)
- KIM 4.4M
- INSM 1.8M
- Earning Date
- KIM 02-07-2025
- INSM 02-20-2025
- Dividend Yield
- KIM 4.69%
- INSM N/A
- EPS Growth
- KIM N/A
- INSM N/A
- EPS
- KIM 0.55
- INSM N/A
- Revenue
- KIM $2,037,014,000.00
- INSM $363,707,000.00
- Revenue This Year
- KIM N/A
- INSM $20.03
- Revenue Next Year
- KIM $4.04
- INSM $41.61
- P/E Ratio
- KIM $38.77
- INSM N/A
- Revenue Growth
- KIM 14.22
- INSM 19.17
- 52 Week Low
- KIM $17.57
- INSM $21.92
- 52 Week High
- KIM $25.83
- INSM $84.87
- Technical
- Relative Strength Index (RSI)
- KIM 36.25
- INSM 58.18
- Support Level
- KIM $21.43
- INSM $79.50
- Resistance Level
- KIM $22.63
- INSM $80.28
- Average True Range (ATR)
- KIM 0.46
- INSM 2.98
- MACD
- KIM -0.05
- INSM 0.06
- Stochastic Oscillator
- KIM 12.21
- INSM 63.38
About KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.